---
title: "\"YuanSi ShengTai\" completes Series B financing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281095552.md"
description: "\"YuanSi ShengTai\" has completed its Series B financing, led by an international biotechnology fund, with Decheng Capital and Dinghui VGC co-leading, and followed by the Abu Dhabi Investment Authority, Temasek, Qiming Venture Partners, and others. Existing shareholders, including AstraZeneca, continue to increase their holdings. The financing will be used to deepen the intelligent iteration of the macrocyclic peptide discovery platform Synova™ and accelerate the transition of the innovative drug pipeline to the clinical stage"
datetime: "2026-03-31T00:44:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281095552.md)
  - [en](https://longbridge.com/en/news/281095552.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281095552.md)
generator: "portal-rs"
---

# "YuanSi ShengTai" completes Series B financing

36Kr learned that "YuanSi ShengTai" announced the completion of its Series B financing. It was led by an international biotechnology fund, with co-leads from Decheng Capital and Dinghui VGC, along with follow-on investments from a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Temasek's wholly-owned subsidiary Dama Capital, Qiming Venture Partners, Boyuan Capital, and other well-known industry investment institutions. Meanwhile, existing shareholders such as AstraZeneca, Eli Lilly Asia Fund, Innovation Works, Wuyuan Capital, Hillhouse Ventures (GL Ventures), Biotech Development Fund, and Lenovo Capital continue to increase their stakes. The funds will be primarily used to deepen the intelligent iteration of its self-developed macrocyclic peptide discovery platform Synova™ and accelerate the conversion of the company's diversified innovative drug pipeline into clinical stages

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [300685.CN](https://longbridge.com/en/quote/300685.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159938.CN](https://longbridge.com/en/quote/159938.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [PJP.US](https://longbridge.com/en/quote/PJP.US.md)
- [XPH.US](https://longbridge.com/en/quote/XPH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [PPH.US](https://longbridge.com/en/quote/PPH.US.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)

## Related News & Research

- [AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China](https://longbridge.com/en/news/297606938.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [AstraZeneca unit AstraZeneca Finance admits EUR 2.55 billion bond offering to London Stock Exchange trading](https://longbridge.com/en/news/297645747.md)
- [REG - AstraZeneca PLC - Admission of Further Securities to Trading](https://longbridge.com/en/news/297665664.md)
- [AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories](https://longbridge.com/en/news/297649754.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**